Clinical efficacy of different drug therapy combined with risperidone and cognitive-behavioral in the treatment of residual schizophrenia

Objective To analyze the clinical efficacy of cognitive behavior research and analysis combined with risperidone in the treatment of residual schizophrenia. Methods One hundred and eighty cases of residual schizophrenia in psychiatric hospital from January,2013 to January,2016 were selected.The treating physician will use a double-blind method.All patients were randomly divided into two groups:Observation group underwent Hydrochloride tablets Schering joint risperidone and cognitive behavioral therapy;the control group underwent clozapine plus risperidone and cognitive behavioral therapy.Two groups of patients were assessed clinically efficacy.The two groups were observed and recorded Hamilton Depression Rating Scale, Anxiety Scale score,individual self-esteem scale score, individual and social function and insight Assessment Scale score. Results After treatment and 1 month to assess the efficacy of clinical observation group clinical efficacy rate (93.33%) was higher (84.44%),the difference was statistically significant (P<0.05).After treatment,the scores, the observation group after treatment Hamilton Depression Scale,Hamilton Anxiety Scale,insight assessment scores were significantly lower than those in the control group,while the observation group after treatment of personal self-esteem scale,individuals and Social Functioning scale scores were significantly higher than those after treatment,the differences were statistically significant (P<0.05). Conclusion Schering joint Hydrochloride tablets risperidone and cognitive behavioral therapy is effective in improving negative symptoms of patients with residual schizophrenia,cognitive social function, improve quality of life for clinicians widely used.